MRM Health Strengthens Board of Directors with Two Industry Veterans as Lead Microbiome Therapy Advances Toward Late-Stage Development
MRM Health, a clinical-stage biotechnology company focused on developing microbiome-based therapeutics for immune-mediated diseases, has announced the appointment of two highly accomplished life sciences executives to its Board of Directors. The leadership expansion comes at a pivotal time for the company as it accelerates the clinical development of its lead therapeutic candidate, MH002, and prepares for the next stage of corporate growth, regulatory engagement, and financing activities.
The company has named Dr. Michel Detheux as Chairman of the Board of Directors, succeeding long-serving Chairman Werner Cautreels, while Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director. Together, the appointments bring decades of expertise spanning biotechnology entrepreneurship, drug development, regulatory strategy, commercial product launches, mergers and acquisitions, capital markets, and microbiome therapeutics.
The strengthened board reflects MRM Health’s ambition to transition from a promising clinical-stage innovator into a leading developer of microbiome-based medicines capable of addressing significant unmet medical needs in immune-mediated gastrointestinal disorders.
Entering a Transformational Stage of Growth
MRM Health has experienced considerable momentum over the past year, positioning the company for a critical period in its evolution. Its lead investigational therapy, MH002, has advanced into Phase 2b clinical development, marking an important step toward potential late-stage clinical trials.
In addition to clinical progress, the company recently achieved another significant milestone when the U.S. Food and Drug Administration granted Fast Track designation to MH002. The designation is intended to facilitate the development and regulatory review of therapies that address serious medical conditions and demonstrate the potential to fulfill unmet medical needs.
The company has also significantly strengthened its financial position after completing a €55 million Series B financing round, providing additional resources to support ongoing clinical studies, expand operational capabilities, and prepare for future development activities.
These achievements have created the need for expanded strategic oversight, making the appointment of experienced board members particularly timely.
CEO Highlights Importance of New Leadership
Dr. Sam Possemiers, Chief Executive Officer of MRM Health, described the appointments as an important milestone that will help guide the company’s next phase of growth.
According to Possemiers, MRM Health is entering a defining chapter as MH002 progresses through mid-stage clinical development while the broader business continues to gain momentum.
He emphasized that both Michel Detheux and Hans-Jürgen Wörle bring complementary expertise across drug development, regulatory affairs, strategic partnerships, capital markets, financing, and corporate transactions. Their combined experience, he noted, will provide valuable guidance as the company advances MH002 through Phase 2b studies, prepares for later-stage clinical development, and pursues future strategic milestones.
Possemiers also expressed confidence in the company’s proprietary CORAL® microbiome platform, stating that the encouraging Phase 2a clinical data generated to date reinforce the belief that MH002 has the potential to become an important next-generation microbiome therapy for immune-mediated diseases.
Dr. Michel Detheux Takes Over as Chairman
As the newly appointed Chairman of the Board, Dr. Michel Detheux brings more than thirty years of experience building biotechnology companies and creating shareholder value through scientific innovation.
Detheux is widely recognized as one of Europe’s accomplished biotechnology entrepreneurs and has successfully guided multiple companies through critical stages of growth.
Among his most notable achievements was serving as the founding Chief Executive Officer of iTeos Therapeutics, where he led the company from its earliest stages through successful venture financing, crossover investment rounds, and ultimately a NASDAQ initial public offering.
During his leadership, iTeos raised approximately $335 million in financing before later securing a landmark $2 billion strategic collaboration with GlaxoSmithKline centered on one of its lead clinical programs.
Beyond iTeos, Detheux continues to play active leadership roles across the biotechnology sector. He currently serves as Chairman of the Board of Egle Therapeutics while also serving as a board member for Vor Bio, providing strategic guidance to companies developing innovative therapies.
His academic background includes a degree in bioengineering, a doctorate in biochemistry from Université Catholique de Louvain, and additional business education through Solvay Business School, combining scientific expertise with commercial leadership experience.
A Strong Belief in the Company’s Scientific Platform
Commenting on his appointment, Dr. Detheux expressed enthusiasm about joining MRM Health at what he considers an exciting point in its development.
He noted that the company occupies a distinctive position where advanced microbiome science, clinical research, and scalable manufacturing capabilities converge.
Detheux highlighted MH002 as a particularly promising therapeutic candidate with the potential to reshape treatment approaches for immune-mediated diseases affecting the gastrointestinal tract.
He also stated that he looks forward to working closely alongside the executive leadership team and fellow board members to help guide the company’s continued expansion and support the successful execution of its long-term strategic vision.
Hans-Jürgen Wörle Brings Extensive Clinical and Regulatory Expertise
Joining the Board as an Independent Director, Prof. Dr. med. Hans-Jürgen Wörle contributes extensive experience spanning clinical medicine, pharmaceutical research and development, microbiome therapeutics, and commercial healthcare innovation.
A board-certified internist specializing in gastroenterology, endocrinology, and diabetology, Wörle has spent decades overseeing drug development programs from early research through regulatory approval and commercialization.
During his tenure as Global Vice President of Medicine at Boehringer Ingelheim, he played a central role in developing several globally successful diabetes medicines, including Jardiance® and Trajenta®.
His leadership helped secure the first FDA-approved cardiovascular mortality claim for a diabetes medication, representing a landmark regulatory achievement within metabolic disease treatment.
More recently, Wörle served as Chief Scientific and Medical Officer at Nestlé Health Science, where he helped transform the organization into a science-driven healthcare company focused on innovative therapeutic solutions.
Experience in the Microbiome Therapeutics Field
One of Wörle’s most significant accomplishments relates directly to MRM Health’s core area of expertise.
At Nestlé Health Science, he played an instrumental role in the development and commercialization of Vowst®, which became the first FDA-approved oral microbiome therapy.
His involvement extended beyond clinical development to include major strategic transactions, licensing agreements, research collaborations, acquisitions, and product commercialization initiatives.
This combination of scientific leadership and business strategy provides MRM Health with valuable experience as it seeks to advance MH002 toward regulatory approval and eventual commercialization.
Wörle has also advised biotechnology companies, executive leadership teams, investors, and corporate boards during important periods of strategic decision-making, helping organizations navigate complex development and financing environments.
Confidence in the Future of Microbiome Medicine
Speaking about his appointment, Wörle emphasized that microbiome science has matured considerably in recent years.
He suggested that the field has progressed beyond demonstrating scientific potential and is now focused on identifying therapies capable of meeting the rigorous clinical and regulatory standards required for widespread patient use.
Having previously helped bring the first approved oral microbiome therapy to market, Wörle believes MRM Health possesses many of the critical ingredients necessary for future success.
He cited the company’s differentiated CORAL® platform together with encouraging MH002 clinical data in inflammatory bowel disease as evidence of a strong scientific foundation supported by disciplined clinical execution.
According to Wörle, MH002 has significant potential to address major unmet needs for patients suffering from immune-mediated gastrointestinal diseases, and he looks forward to helping translate that promise into successful clinical outcomes.
Recognizing Werner Cautreels’ Contributions
Alongside announcing its new appointments, MRM Health also expressed sincere appreciation to Werner Cautreels, who has served as Chairman since the company’s founding in 2020.
During his tenure, Cautreels helped guide the organization through several important milestones, including multiple successful financing rounds, organizational expansion, and the continued advancement of MH002 from early clinical development toward later-stage studies.
His leadership helped establish the foundation upon which the company is now building its next phase of growth.
The transition to new board leadership reflects both continuity and evolution, as MRM Health prepares to execute increasingly ambitious clinical, regulatory, and commercial objectives.
Positioning for the Next Phase of Development
With a strengthened balance sheet, encouraging clinical data, FDA Fast Track designation, and an expanded leadership team, MRM Health appears well positioned for the challenges and opportunities that accompany late-stage drug development.
The appointments of Dr. Michel Detheux and Prof. Dr. Hans-Jürgen Wörle bring together expertise in biotechnology company creation, global clinical development, regulatory strategy, microbiome therapeutics, strategic partnerships, and capital markets. Their combined experience is expected to play an important role as MRM Health advances MH002 through Phase 2b clinical trials and prepares for future regulatory submissions and commercialization efforts.
As interest in microbiome-based therapeutics continues to grow across the biotechnology industry, MRM Health is aiming to establish itself among the leaders developing innovative treatments for immune-mediated diseases. With experienced leadership now in place and a promising clinical pipeline supported by its proprietary CORAL® platform, the company is entering what could become the most consequential chapter in its history.
About MRM Health
MRM Health is a clinical-stage biotech developing innovative Live Biotherapeutic Products (LBPs) for immune-mediated diseases with high unmet needs. Its CORAL® platform enables the design and manufacture of disease-focused microbial consortia with enhanced efficacy and scalability. The Company’s lead program, MH002, for inflammatory bowel diseases (IBD) has shown positive Phase 2a clinical data in ulcerative colitis and pouchitis and is now advancing into late-stage clinical development.
MRM Health is expanding its pipeline across other inflammatory diseases and immune-oncology, leveraging AI-guided discovery and deep expertise in microbiome ecosystem biology. In September 2025, MRM Health successfully closed a €55 million Series B round led by Biocodex, with strong support from ATHOS, BNP Paribas Fortis Private Equity and existing investors SFPIM, AvH, OMX Europe VF, QBIC II and VIB.
